We’re excited to announce the launch of the new BADBIR database, designed to provide a modern, secure, and user-friendly experience for all our users. This upgrade marks a significant step forward in improving reliability, usability, and future scalability.[box...
Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, Catherine H Smith, Richard B Warren, Christopher E M Griffiths, BADBIR study groupBritish Journal of Dermatology, ljaf017, https://doi.org/10.1093/bjd/ljaf017 Related Oras A Alabas, Kayleigh J...
Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...
We will be at the BAD Annual Meeting in Glasgow from the 1st to the 3rd July - come visit us at our stand!You can also attend one of our talks:- Tuesday, 1st July at 10:30 - Prof Warren & Dr Oras Alabas - Hot Topics - Update on new data to inform clinicians on use...
As part of the 14th Substantial Amendment for the study, there have been some changes to the eligibility criteria for patients on conventional treatments. The implementation date for Substantial Amendment 14 is 08/05/2025; these changes will affect any patients...
If a patient recently started on Taltz meets all of our eligibility criteria, they can be recruited.We will review patients who switched from the Conventional cohort onto Taltz, where we have paused their cohort; these patients will now be able to be switched.Please...
Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...
BADBIR will be at the BAD Annual Meeting in Manchester, 2nd-4th JulyCome and visit us on our stand in the exhibition hall, or attend one of our talks:Tues 2nd July; 14:30-15:00: How BADBIR can help answer your research questionWeds 3rd July; 09:00-09:15: The...
We are now accepting patients on Spevigo (spesolimab). Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP). BADBIR can accept registrations for patients with a GPP diagnosis.Please see the eligibility page for...
BADBIR is now open to registrations of patients commencing on the following drugs:Stelara (ustekinumab)Humira (adalimumab)Amgevita (adalimumab)Hulio (adalimumab)Hyrimoz (adalimumab)Idacio (adalimumab)Yuflyma (adalimumab)If a patient is already registered on BADBIR in...
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
